DPP4 inhibitors are probably novel approaches to the treatment of PD and cognitive impairment by targeting specific pathophysiology proteins, such as nuclear receptor related 1 (Nurr1), PTEN-induced putative kinase 1 (PINK1), and Nrf2 (153). The gene discussed is PINK1; the disease is Cognitive impairment.